From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Combination of
SertralineSelective serotonin reuptake inhibitor
AripiprazoleAtypical antipsychotic
Clinical data
Other namesASC-01
Routes of
By mouth
Legal status
Legal status

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] The drug combines serotonin reuptake inhibition and modulation of dopamine and serotonin receptors.[1] As of July 2017, it is in preregistration in Japan for the treatment of MDD.[1]

See also[edit]


External links[edit]